RESEARCH MONOGRAPH · KDC-MN-367

Abaloparatide

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

78/100

PTHrP-based analog with a faster anabolic profile and arguably better cortical bone effect than teriparatide

Abaloparatide is a synthetic 34-residue analog of parathyroid hormone-related protein (PTHrP 1-34), engineered for selective signaling through the PTH1 receptor in a way that biases toward anabolic over catabolic effects. The pharmacology rationale is that PTHrP and PTH activate the same receptor but with different conformational preferences, and that the PTHrP-biased signaling produces a cleaner anabolic profile with less resorption activation than full PTH 1-34.

Mechanistically, the bias is real. The receptor conformational selection (R-zero versus R-G states) shifts the downstream signaling balance, and the result in the ACTIVE trial (Miller et al, JAMA 2016) was that abaloparatide produced larger BMD gains at hip and femoral neck than teriparatide at equivalent comparator dosing, with comparable vertebral spine effects and a shorter time to fracture risk reduction. The relative cortical versus trabecular bone effect is one of the more interesting comparative pharmacology stories in this space.

The fracture reduction data in the ACTIVE trial was clear. Vertebral fracture reduction around 86 percent versus placebo, non-vertebral around 43 percent, and the effect emerged earlier than typical for anabolic agents.

What we find interesting from a research angle is the PTHrP biology this drug exploits. PTHrP is the physiologically relevant ligand for PTH1R in many tissues outside of calcium homeostasis (cartilage development, breast biology, vascular smooth muscle), and the receptor biased signaling work informs broader questions about GPCR pharmacology that go well beyond bone. The Gardella, Vilardaga, and Jueppner labs have published extensively on the conformational selection model.

Sourcing as a research peptide is straightforward. 34 residues, the proprietary clinical formulation (Tymlos) is one option, research-grade PTHrP analogs are available from peptide vendors with proper HPLC validation. The PEGylated formulations are different chemistry and worth distinguishing.

What we dont love is the cost positioning relative to teriparatide, which has had less impact on prescribing than the comparative efficacy data probably warrants. The two are reasonable alternatives clinically and the choice often comes down to access rather than pharmacology.

From a research standpoint, abaloparatide is a useful tool for studying PTH1R biased signaling and the receptor conformational selection model. Underused as a probe in non-bone PTH1R biology, honestly.

Evidence: 85
Mechanism: 88
Reliability: 85
Safety: 80
Sourcing: 75
Value: 60
Signal: 75
Staying power: 78

Plain-language summary Intrigue 58 / 100

Abaloparatide, sold as Tymlos, is a modified analog of parathyroid hormone-related protein (a relative of PTH) with substitutions at nine positions designed to make it bind the PTH1 receptor with selectivity for the transient signaling state. The functional consequence is more anabolic and less catabolic effect compared to teriparatide, theoretically offering better bone formation with less bone resorption. Head-to-head ACTIVE trial data showed similar fracture reduction to teriparatide with a different side effect profile. Approved by the FDA in 2017, it occupies the same niche as teriparatide for severe osteoporosis. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Synthetic PTHrP 1-34 analog

A modified parathyroid hormone-related protein (PTHrP) 1-34 analog with PTH1R receptor selectivity for the RG conformation; an anabolic bone agent.

Abstract

Abaloparatide (BA058; modified PTHrP 1-34 analog with substitutions at positions 12, 19, 22, 23, 25, 26, 28, 29, 33; molecular weight approximately 3961 Da) is a synthetic analog of parathyroid hormone-related protein 1-34 developed at Radius Health and approved by the FDA in 2017 (Tymlos). The compound binds the PTH1 receptor (PTH1R) with selectivity for the transient RG (G-protein coupled) conformation over the prolonged R0 conformation favored by teriparatide; this RG selectivity is hypothesized to produce shorter-lived but more anabolic-favoring receptor signaling. Approved for severe osteoporosis with high fracture risk. The ACTIVE trial demonstrated comparable fracture reduction to teriparatide with possibly faster onset and reduced hypercalcemia incidence. Plasma half-life is approximately 1 hour. The 18-month treatment course mirrors teriparatide's cumulative-dose limitation. Used as a reference RG-selective PTH1R agonist.

Mechanism of action

Modified PTHrP 1-34 analog; PTH1R RG-conformation selective; transient receptor signaling favoring anabolic over catabolic effects.

Reported research dose ranges

Clinical 80 mcg subcutaneous for up to 18 months.

References

Miller PD, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis (ACTIVE). JAMA 2016.
Hattersley G, et al. Binding selectivity of abaloparatide for PTH-Type-1-Receptor conformations and effects on downstream signaling. Endocrinology 2016.
Cosman F, et al. Anabolic agents for postmenopausal osteoporosis. Endocrinol Metab Clin North Am 2017.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-367

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Abaloparatide

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs